{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:27:43Z","timestamp":1767598063854},"publisher-location":"Chichester, UK","reference-count":107,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003426.pub3","type":"reference-entry","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T15:51:00Z","timestamp":1263829860000},"source":"Crossref","is-referenced-by-count":8,"title":["Drugs for preventing red blood cell dehydration in people with sickle cell disease"],"prefix":"10.1002","author":[{"given":"Srikanth","family":"Nagalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir K","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD003426.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2007-08-110098","article-title":"Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia","volume":"111","author":"Ataga","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD003426.pub3-BIB2|cit2","first-page":"467","article-title":"Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial","volume":"43","author":"Gupta","year":"1995","journal-title":"Journal of the Association of Physicians of India"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00000441-197305000-00002","article-title":"The effect of megestrol acetate on sickling","volume":"265","author":"Adadevoh","year":"1973","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD003426.pub3-BIB5|cit4","series-title":"Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program; March 1995","first-page":"118","article-title":"Rheothrx (Poloxamer 188) injection for the acute painful episode of sickle cell disease (SCD): a pilot study [abstract]","author":"Adams-Graves","year":"1995"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub3-BIB4|cit5","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V90.5.2041","article-title":"RheothRx (Poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study","volume":"90","author":"Adams-Graves","year":"1997","journal-title":"Blood"},{"issue":"Suppl","key":"10.1002\/14651858.CD003426.pub3-BIB6|cit6","first-page":"410a","article-title":"RheothRx\u00ae (poloxamer 188) injection for the acute painful episode of sickle cell disease","volume":"84","author":"Adams-Graves","year":"1994","journal-title":"Blood"},{"issue":"10 (Suppl 1)","key":"10.1002\/14651858.CD003426.pub3-BIB7|cit7","first-page":"13a","article-title":"RheothRx (Poloxamer 188) lowers serum LDH during an acute painful episode of sickle cell disease [abstract]","volume":"88","author":"Emanuele","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/tropej\/fmh097","article-title":"Clinical evaluation of extract of Cajanus cajan (Ciklavit) in sickle cell anaemia","volume":"51","author":"Akinsulie","year":"2005","journal-title":"Journal of Tropical Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB9|cit9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5144\/0256-4947.1999.97","article-title":"Isoxsuprine in the treatment of sickle cell painful crises: a double-blind comparative study with narcotic analgesia","volume":"19","author":"Al-Jam'a","year":"1999","journal-title":"Annals of Saudi Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB10|cit10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000084675","article-title":"Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease","volume":"113","author":"Alvim","year":"2005","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD003426.pub3-BIB11|cit11","series-title":"Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program","first-page":"41a","article-title":"A phase 1B randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of IC 17043 in patients with sickle cell disease (SCD) [abstract]","author":"Ataga","year":"2002"},{"issue":"11 (Part 1 of 2","key":"10.1002\/14651858.CD003426.pub3-BIB12|cit12","first-page":"454a","article-title":"A phase 1B randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of ICA-17043 in patients with sickle cell disease (SCD) [abstract]","volume":"100","author":"Ataga","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1046\/j.1365-2141.1996.d01-1744.x","article-title":"Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia","volume":"93","author":"Arya","year":"1996","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003426.pub3-BIB14|cit14","series-title":"35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA","first-page":"346","article-title":"The effect of guided imagery on pain in children [abstract]","author":"Beatty","year":"2007"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood.V67.5.1442.1442","article-title":"A collaberative, double-blind randomized study of cetiedil citrate in sickle cell crisis","volume":"67","author":"Benjamin","year":"1986","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD003426.pub3-BIB16|cit16","first-page":"403","article-title":"Pentoxifylline (Trental) has no significant effect on laboratory parameters in sickle cell disease","volume":"31","author":"Billett","year":"1989","journal-title":"Nouvelle Revue Francaise d'Hematologie"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB17|cit17","first-page":"207","article-title":"Acute painful sickle-cell crises in children: a double-blind, placebo-controlled evaluation of efficacy and safety of cetiedil","volume":"20","author":"Cabannes","year":"1983","journal-title":"Clinical Trials Journal"},{"key":"10.1002\/14651858.CD003426.pub3-BIB18|cit18","first-page":"199","article-title":"Clinical and biological double-blind-study of Ticlopidine in preventive treatment of sickle cell disease crises","volume":"15","author":"Cabannes","year":"1984","journal-title":"Agents and Actions Supplements"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0010-7824(97)00156-X","article-title":"Effect of Depo-Provera\u00ae or Microgynon\u00ae on the painful crises of sickle cell anemia patients","volume":"56","author":"Abood","year":"1997","journal-title":"Contraception"},{"issue":"8292","key":"10.1002\/14651858.CD003426.pub3-BIB20|cit20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(82)90320-8","article-title":"Medroxyprogesterone acetate and homozygous sickle cell disease","volume":"2","author":"Ceulaer","year":"1982","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003426.pub3-BIB21|cit21","series-title":"Proceedings of the Commonwealth Caribbean Medical Research Council, 27th Scientific Meeting; 1982 April 14-17; Trinidad and Tobago","first-page":"47","article-title":"Effect of depo-provera on the haematological and clinical features of homozygous sickle cell disease [abstract]","author":"Ceulaer","year":"1982"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub3-BIB22|cit22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/CH-1990-10104","article-title":"Intravenous oxypentifylline and the painful crisis of sickle cell disease","volume":"10","author":"Ceulaer","year":"1990","journal-title":"Clinical Hemorheology"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0021-9681(82)90115-1","article-title":"A double-blind randomized trial of low-dose urea to prevent sickle cell crises","volume":"35","author":"Gail","year":"1982","journal-title":"Journal of Chronic Diseases"},{"key":"10.1002\/14651858.CD003426.pub3-BIB24|cit24","series-title":"Blood","first-page":"2824a","article-title":"Assessment of ketoprofen for acute vaso-occlusive crisis in adult patients with sickle cell disease. A randomized double blind monocentric study","author":"Godeau","year":"2003"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB26|cit25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000208633","article-title":"The effect of certain lipid substances on sickling","volume":"45","author":"Isaacs","year":"1971","journal-title":"Acta Haematologica"},{"issue":"7750","key":"10.1002\/14651858.CD003426.pub3-BIB25|cit26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0140-6736(72)90359-5","article-title":"Steroid treatment in the prevention of painful episodes in sickle-cell disease","volume":"1","author":"Isaacs","year":"1972","journal-title":"Lancet"},{"issue":"9088","key":"10.1002\/14651858.CD003426.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(97)08462-6","article-title":"Randomised trial of oral morphine for painful episodes of sickle-cell disease in children","volume":"350","author":"Jacobson","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clpt.2003.10.007","article-title":"Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease","volume":"75","author":"Kopesky","year":"2004","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD003426.pub3-BIB29|cit29","first-page":"213","article-title":"Beneficial effects of Ticlopidine on cardiopulmonary function of sickle cell patients not in crisis","volume":"15","author":"Lonsdorfer","year":"1984","journal-title":"Agents and Actions Supplements"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.1969.tb00391.x","article-title":"A double-blind trial of a phenothiazine compound in the treatment of clinical crisis of sickle cell anaemia","volume":"16","author":"Mahmood","year":"1969","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003426.pub3-BIB31|cit31","series-title":"Proceedings of the 24th Annual Meeting of the National Sickle Cell Disease Program","first-page":"172a","article-title":"Aspartame inhibits hypoxia-induced sickling of erythrocytes in patients with sickle cell disease [abstract]","author":"Manion","year":"2000"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1067\/mcp.2001.115141","article-title":"Aspartame effect in sickle cell anemia","volume":"69","author":"Manion","year":"2001","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"5&6","key":"10.1002\/14651858.CD003426.pub3-BIB33|cit33","first-page":"277","article-title":"Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients","volume":"18","author":"Manrique","year":"1987","journal-title":"Journal of Medicine"},{"key":"10.1002\/14651858.CD003426.pub3-BIB34|cit34","series-title":"Proceedings of the 16th Annual Meeting of the National Sickle cell Disease Program","first-page":"112","article-title":"A clinical study of the safety, pharmacokinetics and pharmacodynamics of intravenous infusions of 12C79 in sickle cell disease patients not in crisis [abstract]","author":"Orringer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003426.pub3-BIB35|cit35","first-page":"69a","article-title":"Phase 1 study of BW 12C in sickle cell disease (SCD) patients not in crisis [abstract]","volume":"5","author":"Orringer","year":"1988","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003426.pub3-BIB36|cit36","series-title":"Proceedings of the 14th Annual Meeting of the National Sickle Cell Disease Program","first-page":"57","article-title":"Phase I study of 12C79 in sickle cell disease (SCD) patients not in crisis [abstract]","author":"Orringer","year":"1989"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB37|cit37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000207105","article-title":"Therapeutic effect of aspirin in sickle cell anaemia","volume":"66","author":"Osamo","year":"1981","journal-title":"Acta Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB38|cit38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0022-3476(68)80083-6","article-title":"Failure of promazine HCl to prevent the painful episodes in sickle cell anemia","volume":"73","author":"Oski","year":"1968","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub3-BIB39|cit39","first-page":"249","article-title":"Therapeutic effect of diflusinal as prophylaxis in sickle cell anaemia","volume":"24","author":"Oyewo","year":"1987","journal-title":"Clinical Trials Journal"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10321","article-title":"Effects of N-acetylcysteine on dense cell formation in sickle cell disease","volume":"73","author":"Pace","year":"2003","journal-title":"American Journal of Hematology"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub3-BIB41|cit41","first-page":"834","article-title":"Effectiveness of treatment during osteoarticular pain crises in drepanocytosis; based on the example of pentoxifylline","volume":"80","author":"Pichard","year":"1987","journal-title":"Bulletin de la Societe de Pathologie Exotique et de ses Filiales (Paris)"},{"key":"10.1002\/14651858.CD003426.pub3-BIB42|cit42","series-title":"Proceedings of the 20th Annual Meeting of the National Sickle Cell Disease Program","first-page":"162a","article-title":"Piracetam in the treatment of sickle cell disease [abstract","author":"El-Hazmi","year":"1995"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB43|cit43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000203788","article-title":"Piracetam is useful in the treatment of children with sickle cell disease","volume":"96","author":"El-Hazmi","year":"1996","journal-title":"Acta Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub3-BIB44|cit44","first-page":"22","article-title":"Piracetam for the treatment of sickle cell disease in children - a double blind test","volume":"19","year":"1998","journal-title":"Saudi Medical Journal"},{"issue":"8","key":"10.1002\/14651858.CD003426.pub3-BIB45|cit45","first-page":"608","article-title":"Haemorheological treatment of painful sickle cell crises: use of pentoxifylline","volume":"39","author":"Poflee","year":"1991","journal-title":"Journal of the Association of Physicians India"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB46|cit46","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial","volume":"98","author":"Qari","year":"2007","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub3-BIB47|cit47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2165\/00003088-199222030-00006","article-title":"Prediction of diltiazem plasma concentration curves from limited measurements using compliance data","volume":"22","author":"Rubio","year":"1992","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD003426.pub3-BIB48|cit48","first-page":"47","article-title":"Scoring system in a pilot effectiveness study of patients with sickle cell anemia","volume":"6","author":"Rubio","year":"1992","journal-title":"Journal of Clinical Research and Pharmacoepidemiology"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub3-BIB49|cit49","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-0038-1661088","article-title":"A double-blind trial of Ticlopidine in sickle cell disease","volume":"51","author":"Semple","year":"1984","journal-title":"Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003426.pub3-BIB50|cit50","first-page":"298","article-title":"Hydroxyurea treatment of sickle cell diseases causes megaloblastic transformation of the bone marrow that is responsible for the increase of the mean corpuscular volume [abstract]","volume":"92","author":"Silva-Pinto","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB51|cit51","first-page":"320","article-title":"Double blind randomised clinical trial of pentoxiphyllin in vaso-occlusive sickle cell crisis","volume":"41","author":"Teuscher","year":"1989","journal-title":"Tropical and Geographical Medicine"},{"issue":"9226","key":"10.1002\/14651858.CD003426.pub3-BIB52|cit52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(00)02508-3","article-title":"Antisickling activity of sodium cromoglicate in sickle-cell disease [letter]","volume":"356","author":"Toppet","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub3-BIB53|cit53","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jama.1974.03230340022022","article-title":"Clinical trials of therapy for sickle cell vaso-occlusive crises","volume":"228","year":"1974","journal-title":"Journal of the American Medical Association"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub3-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.1974.03230340027023","article-title":"Treatment of sickle cell crisis with urea in invert sugar. A controlled trial.","volume":"228","year":"1974","journal-title":"Journal of the American Medical Association"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub3-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/jama.1974.03230340031024","article-title":"Controlled clinical trials and cooperative study of intravenously administered alkali","volume":"228","year":"1974","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD003426.pub3-BIB56|cit56","series-title":"35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA.","first-page":"261","article-title":"A randomized pilot study exploring hypnosis as a pain and symptom management strategy in patients with sickle cell disease [abstract]","author":"Wallen","year":"2007"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB57|cit57","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1211\/fact.2002.00158","article-title":"Indigenous Nigerian medicinal plants may be useful in the management of sickle-cell disorder","volume":"7","author":"Fonnebo","year":"2002","journal-title":"Focus on Alternative and Complementary Therapies"},{"key":"10.1002\/14651858.CD003426.pub3-BIB59|cit58","series-title":"Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program","first-page":"46a","article-title":"Chemistry and clinical evaluation of NIPRISAN in patients with sickle cell anemia [abstract]","author":"Wambebe","year":"2002"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB58|cit59","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1078\/0944-7113-00040","article-title":"Double-blind, placebo-controlled, randomised cross-over clinical trial of Niprisan in patients with sickle cell disorder","volume":"8","author":"Wambebe","year":"2001","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub3-BIB60|cit60","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0011-393X(01)80039-4","article-title":"Efficacy of niprisan in the prophylactic management of patients with sickle cell disease","volume":"62","author":"Wambebe","year":"2001","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD003426.pub3-BIB61|cit61","first-page":"11a","article-title":"Inhaled nitric oxide for treatment of acute vaso-occlusive crisis in sickle cell disease [abstract]","volume":"100","author":"Weiner","year":"2002","journal-title":"Blood"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003426.pub3-BIB62|cit62","first-page":"86A","article-title":"Effectiveness and safety of inhaled nitric oxide for the treatment of vaso-occlusive crisis in pediatric sickle cell disease [abstract]","volume":"51","author":"Weiner","year":"2002","journal-title":"Pediatric Research"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub3-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.289.9.1136","article-title":"Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease","volume":"289","author":"Weiner","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003426.pub3-BIB64|cit64","series-title":"35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA.","first-page":"245","article-title":"Recruitment in the baby hug pediatric hydroxyurea phase 3 clinical trial [abstract]","author":"Wynn","year":"2007"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub3-BIB65|cit65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000206360","article-title":"Treatment of sickle cell diseases wih aspirin","volume":"72","author":"Zago","year":"1984","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD003426.pub3-BIB66|cit66","unstructured":"Ballas SKB personal communication 2009"},{"issue":"10, Suppl 1, Pa","key":"10.1002\/14651858.CD003426.pub3-BIB67|cit67","first-page":"200a","article-title":"Administration of magnesium aspartate in patients with HbS\/B-Thalassemia normalizes the RBC density distribution and removes dense sickle cells from the peripheral blood [abstract]","volume":"94","author":"Nodaros","year":"1999","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003426.pub3-BIB68|cit68","series-title":"Proceedings of the 5th Congress of the European Haematology Association (EHA); 2000 June 25-28; Birmingham, UK","article-title":"Administration of magnesium aspartate in patients with HbS\/b-Thalassaemia results in normalization of the red cell density distribution curves and removal of the dense sickle cells from the peripheral blood [abstract]","author":"Voskaridou","year":"2000"},{"issue":"11","key":"10.1002\/14651858.CD003426.pub3-BIB69|cit69","first-page":"Parts 1 and 2","article-title":"Nitric oxide restores the erythrocyte density of the SAD mouse model of sickle cell disease [abstract]","volume":"96","author":"Adrie","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB70|cit70","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006111.pub2","article-title":"Piracetam for reducing the incidence of painful sickle cell disease crises","author":"Al Hajeri","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB71|cit71","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ajh.2830320206","article-title":"Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo","volume":"32","author":"Ballas","year":"1989","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD003426.pub3-BIB72|cit72","first-page":"Parts 1 and 2","article-title":"Hydration of sickle erythrocytes using a naturally occurring sodium ionophore [abstract]","volume":"96","author":"Ballas","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub3-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood.V95.5.1842.005a37_1842_1848","article-title":"Volume control in sickle cells is facilitated by novel anion conductance inhibitor NS1652","volume":"95","author":"Bennekou","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub3-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1182\/blood.V97.5.1451","article-title":"Treatment with NS3623, a novel Cl-conductance blocker, amiliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease","volume":"97","author":"Bennekou","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD003426.pub3-BIB75|cit75","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood.V70.6.1810.1810","article-title":"Inhibition of K transport by divalent cations in sickle erythrocytes","volume":"70","author":"Brugnara","year":"1987","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub3-BIB76|cit76","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1172\/JCI116597","article-title":"Inhibition of Ca2+activated K + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives","volume":"92","author":"Brugnara","year":"1993","journal-title":"Journal of Clinical Investigation"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB77|cit77","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00062752-199502020-00005","article-title":"Red cell dehydration in pathophysiology and treatment of sickle cell disease","volume":"2","author":"Brugnara","year":"1995","journal-title":"Current Opinion in Hematology"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub3-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1172\/JCI118537","article-title":"Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease","volume":"97","author":"Brugnara","year":"1996","journal-title":"Journal of Clinical Investigation"},{"issue":"20","key":"10.1002\/14651858.CD003426.pub3-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD003426.pub3-BIB80|cit80","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/bmj.315.7109.656","article-title":"Management of patients with sickle cell disease","volume":"315","author":"Davies","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1172\/JCI117149","article-title":"Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease.","volume":"93","author":"Franceschi","year":"1994","journal-title":"Journal of Clinical Investigation"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub3-BIB82|cit82","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD003426.pub3-BIB83|cit83","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1182\/blood.V91.11.4373","article-title":"The efficacy of reducing agents or antioxidants in blocking the formation of dense cells and irreversibly sickled cells in vitro","volume":"91","author":"Gibson","year":"1998","journal-title":"Blood"},{"issue":"2-3","key":"10.1002\/14651858.CD003426.pub3-BIB84|cit84","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0014-5793(00)01930-X","article-title":"Effect of dimethyl adipimidate on K+ transport and shape change in red blood cells from sickle cell patients","volume":"480","author":"Gibson","year":"2000","journal-title":"FEBS Letters"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub3-BIB85|cit85","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/jcp.40.1.99","article-title":"Use of piracetam improves sickle cell deformability in vitro and in vivo","volume":"40","author":"Gini","year":"1987","journal-title":"Journal of Clinical Pathology"},{"key":"10.1002\/14651858.CD003426.pub3-BIB86|cit86","first-page":"477","article-title":"Red blood cell survival, zinc deficiency and efficacy of zinc therapy in sickle cell disease","volume-title":"Thalassemia: pathophysiology and management, part A","volume":"23","author":"Gupta","year":"1987"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub3-BIB87|cit87","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2007.06884.x","article-title":"Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia.","volume":"140","author":"Hankins","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB88|cit88","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.1999.01275.x","article-title":"Mapping the prevalence of sickle cell disease and beta thalassaemia in England: estimating and validating ethnic-specific rates","volume":"104","author":"Hickman","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"7414","key":"10.1002\/14651858.CD003426.pub3-BIB89|cit89","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB90|cit90","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002202","article-title":"Hydroxyurea for sickle cell disease","author":"Jones","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7850","key":"10.1002\/14651858.CD003426.pub3-BIB91|cit91","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(74)92518-5","article-title":"Plasma-zinc in sickle cell-anaemia [letter]","volume":"1","author":"Karayalcin","year":"1974","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub3-BIB92|cit92","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1542\/peds.84.3.500","article-title":"Mortality in children and adolescents with sickle cell disease","volume":"84","author":"Leikin","year":"1989","journal-title":"Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB93|cit93","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ajh.2830100203","article-title":"Effect of zinc supplementation on serum testosterone level in adult male sickle cell anemia subjects","volume":"10","author":"Prasad","year":"1981","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub3-BIB94|cit94","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<194::AID-AJH6>3.0.CO;2-C","article-title":"Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD)","volume":"61","author":"Prasad","year":"1999","journal-title":"American Journal of Hematology"},{"issue":"11 (Pt 1 and 2)","key":"10.1002\/14651858.CD003426.pub3-BIB95|cit95","article-title":"Decreased exhaled nitric oxide (NO) in patients with sickle cell disease [abstract]","volume":"96","author":"Qureshi","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003426.pub3-BIB96|cit96","series-title":"Blood","article-title":"Vaso-active molecules modulate Gardos channel activity and hydration state of normal and sickle erythrocytes","author":"Rivera","year":"2000"},{"issue":"11 (Pt 1 and 2)","key":"10.1002\/14651858.CD003426.pub3-BIB97|cit97","article-title":"Arginine supplementation of sickle transgenic mice: effects on red cell density and potassium transport [abstract]","volume":"96","author":"Romero","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB98|cit98","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood.V99.4.1103","article-title":"Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity","volume":"99","author":"Romero","year":"2002","journal-title":"Blood"},{"issue":"7679","key":"10.1002\/14651858.CD003426.pub3-BIB99|cit99","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0140-6736(70)92067-2","article-title":"Oral zinc sulphate in sickle-cell ulcers","volume":"2","author":"Serjeant","year":"1970","journal-title":"Lancet"},{"volume-title":"Sickle cell disease","year":"1992","author":"Serjeant","key":"10.1002\/14651858.CD003426.pub3-BIB100|cit100"},{"issue":"11 (Pt 1 and 2)","key":"10.1002\/14651858.CD003426.pub3-BIB101|cit101","article-title":"A novel Gardos channel inhibitor, ICA-17043, prevents red blood cell dehydration in vitro and in a mouse model (SAD) of sickle cell disease [abstract]","volume":"96","author":"Stocker","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD003426.pub3-BIB102|cit102","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2002-05-1433","article-title":"ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice","volume":"101","author":"Stocker","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub3-BIB103|cit103","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/CH-1988-8524","article-title":"Action of piracetam on cation flux and deformability of sickle cells","volume":"8","author":"Stone","year":"1988","journal-title":"Clinical Hemorheology"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub3-BIB104|cit104","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3233\/CH-1990-10510","article-title":"Effect of Piracetam on Ca2+-induced K+ efflux from sickle cells","volume":"10","author":"Stuart","year":"1990","journal-title":"Clinical Hemorheology"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub3-BIB105|cit105","first-page":"203","article-title":"Rheological consequences of sickle-cell dehydration","volume":"12","author":"Stuart","year":"1992","journal-title":"Clinical Hemorheology"},{"key":"10.1002\/14651858.CD003426.pub3-BIB106|cit106","series-title":"Proceedings of the 25th Annual Meting of the National Sickle Cell Disease Program; April 2001; New York","first-page":"Abst #232","article-title":"Zinc supplementation and linear growth in children with sickle cell disease: a pilot study [abstract]","author":"Zemel","year":"2001"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub3-BIB107|cit107","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003426","article-title":"Drugs for preventing red blood cell dehydration in people with sickle cell disease","author":"Riddington","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003426.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T23:25:49Z","timestamp":1711149949000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003426.pub3"}},"subtitle":[],"editor":[{"given":"Samir K","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":107,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003426.pub3","relation":{},"subject":[],"published":{"date-parts":[[2010,1,20]]}}}